Head to head comparison of the formulation and stability of concentrated solutions of HESylated versus PEGylated anakinra.
暂无分享,去创建一个
Gerhard Winter | G. Winter | Ahmed Besheer | Martin Meyer | T. Hey | Ahmed Besheer | Robert Liebner | Martin Meyer | Thomas Hey | R. Liebner
[1] R. Rudolph,et al. Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. , 2005, Trends in biotechnology.
[2] A. Pappenberger,et al. Degradation of polysorbates 20 and 80: studies on thermal autoxidation and hydrolysis. , 2011, Journal of pharmaceutical sciences.
[3] P. Pranay,et al. Characterization of protein rheology and delivery forces for combination products. , 2012, Journal of pharmaceutical sciences.
[4] A. Skerra. Alternative non-antibody scaffolds for molecular recognition. , 2007, Current opinion in biotechnology.
[5] B. Chang,et al. Mechanism for benzyl alcohol-induced aggregation of recombinant human interleukin-1 receptor antagonist in aqueous solution. , 2004, Journal of Pharmacy and Science.
[6] H. Senn,et al. Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers. , 2005, Bioconjugate chemistry.
[7] M. Scholle,et al. Gcg-XTEN: An Improved Glucagon Capable of Preventing Hypoglycemia without Increasing Baseline Blood Glucose , 2010, PloS one.
[8] Y. Levy,et al. Folding of glycoproteins: toward understanding the biophysics of the glycosylation code. , 2009, Current opinion in structural biology.
[9] G. McKinley,et al. Microfluidic rheometry , 2008 .
[10] Sandeep Yadav,et al. Specific interactions in high concentration antibody solutions resulting in high viscosity. , 2010, Journal of pharmaceutical sciences.
[11] M. Emgenbroich,et al. Erythropoietin mimetic compound AGEM400(HES) binds to the same receptor as erythropoietin but displays a different spectrum of activities. , 2012, Cytokine.
[12] W. Berthold,et al. Polyethylene glycol-conjugated pharmaceutical proteins , 1998 .
[13] G. Hause,et al. Hydrophobically modified hydroxyethyl starch: synthesis, characterization, and aqueous self-assembly into nano-sized polymeric micelles and vesicles. , 2007, Biomacromolecules.
[14] F. Davis,et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. , 1977, The Journal of biological chemistry.
[15] Haeshin Lee,et al. N-Terminal Site-Specific Mono-PEGylation of Epidermal Growth Factor , 2003, Pharmaceutical Research.
[16] W. Kulicke,et al. Measurements of the refractive index increment on hydroxyethyl starch as a basis for absolute molecular weight determinations , 1991 .
[17] Guifeng Zhang,et al. Investigation on PEGylation strategy of recombinant human interleukin-1 receptor antagonist. , 2007, Bioorganic & medicinal chemistry.
[18] Z. Su,et al. PEGylation of rhIL-1RA increased its solution stability at room temperature , 2009 .
[19] I. Theobald,et al. Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. , 2007, Protein engineering, design & selection : PEDS.
[20] D. Rudmann,et al. High Molecular Weight Polyethylene Glycol Cellular Distribution and PEG-associated Cytoplasmic Vacuolation Is Molecular Weight Dependent and Does Not Require Conjugation to Proteins , 2013, Toxicologic pathology.
[21] F. Veronese,et al. PEGylated Protein Drugs: Basic Science and Clinical Applications , 2009 .
[22] Steven J Shire,et al. Challenges in the development of high protein concentration formulations. , 2004, Journal of pharmaceutical sciences.
[23] B. Luxon,et al. Pegylated interferons for the treatment of chronic hepatitis C infection. , 2002, Clinical therapeutics.
[24] G. Shopp,et al. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.
[25] J. Bi,et al. Facile purification of mono-PEGylated interleukin-1 receptor antagonist and its characterization with multi-angle laser light scattering , 2007 .
[26] Wei Liu,et al. High‐throughput measurement, correlation analysis, and machine‐learning predictions for pH and thermal stabilities of Pfizer‐generated antibodies , 2011, Protein science : a publication of the Protein Society.
[27] J. Freed,et al. Characterization of a low molecular weight isoform of IL-1 receptor antagonist. , 1998, Journal of immunology.
[28] H. Bunjes,et al. Comparison of different protein concentration techniques within preformulation development. , 2011, International journal of pharmaceutics.
[29] D. Brems,et al. Characterization and Stability of N-terminally PEGylated rhG-CSF , 1996, Pharmaceutical Research.
[30] Gerhard Winter,et al. Influence of hydroxypropyl-Beta-cyclodextrin on the stability of dilute and highly concentrated immunoglobulin g formulations. , 2013, Journal of pharmaceutical sciences.
[31] D. Wuttke,et al. High concentration formulations of recombinant human interleukin-1 receptor antagonist: I. Physical characterization. , 2008, Journal of pharmaceutical sciences.
[32] R. P. Garay,et al. Immunogenicity of Polyethylene Glycol (PEG) , 2011 .
[33] G. Winter,et al. Challenges for PEGylated Proteins and Alternative Half-Life Extension Technologies Based on Biodegradable Polymers , 2013 .
[34] P. Kingshott,et al. Characterisation and physical stability of PEGylated glucagon. , 2007, International journal of pharmaceutics.
[35] A. Plückthun,et al. Protein PEGylation Decreases Observed Target Association Rates via a Dual Blocking Mechanisms⃞ , 2005, Molecular Pharmacology.
[36] Zai-Qing Wen,et al. Conformation and side chains environments of recombinant human interleukin-1 receptor antagonist (rh-IL-1ra) probed by raman, raman optical activity, and UV-resonance Raman spectroscopy. , 2008, Journal of pharmaceutical sciences.
[37] Hanns-Christian Mahler,et al. Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.
[38] J. Engberts,et al. Aqueous solutions that model the cytosol: studies on polarity, chemical reactivity and enzyme kinetics. , 2004, Organic & biomolecular chemistry.
[39] R. Kontermann,et al. Strategies for extended serum half-life of protein therapeutics. , 2011, Current opinion in biotechnology.
[40] L. Setton,et al. Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: sustained release of a local antiinflammatory therapeutic. , 2007, Arthritis and rheumatism.
[41] Wolfgang Friess,et al. High-throughput melting-temperature analysis of a monoclonal antibody by differential scanning fluorimetry in the presence of surfactants. , 2013, Journal of pharmaceutical sciences.
[42] Jan Jezek,et al. Viscosity of concentrated therapeutic protein compositions. , 2011, Advanced drug delivery reviews.
[43] T. Arakawa,et al. Formation of an active dimer during storage of interleukin-1 receptor antagonist in aqueous solution. , 1996, Biophysical journal.
[44] T. Palm,et al. The effect of PEGylation on the stability of small therapeutic proteins , 2011, Pharmaceutical development and technology.
[45] Deirdre Murphy Piedmonte,et al. Formulation of Neulasta (pegfilgrastim). , 2008, Advanced drug delivery reviews.
[46] B. Manjula,et al. Non-hypertensive tetraPEGylated canine haemoglobin: correlation between PEGylation, O2 affinity and tissue oxygenation. , 2007, The Biochemical journal.
[47] Theodore W Randolph,et al. High concentration formulations of recombinant human interleukin-1 receptor antagonist: II. Aggregation kinetics. , 2008, Journal of pharmaceutical sciences.
[48] R. Kontermann. Strategies to Extend Plasma Half-Lives of Recombinant Antibodies , 2012, BioDrugs.
[49] Ken A. Dill,et al. Theory for the aggregation of proteins and copolymers , 1992 .
[50] D. Brems,et al. Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study , 2006, Protein science : a publication of the Protein Society.
[51] B. Stockman,et al. Solution structure of human interleukin‐1 receptor antagonist protein , 1994, FEBS Letters.
[52] T. Hey,et al. Half‐Life Extension through HESylation® , 2012 .
[53] C. Klofutar,et al. Viscosity of aqueous solutions of poly(ethylene glycol)s at 298.15 K , 1999 .
[54] Steven J Shire,et al. Formulation and manufacturability of biologics. , 2009, Current opinion in biotechnology.
[55] G. Gregoriadis,et al. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. , 2005, International journal of pharmaceutics.
[56] Roman Mathaes,et al. Protein HESylation for half-life extension: synthesis, characterization and pharmacokinetics of HESylated anakinra. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[57] Bruce A Kerwin,et al. Anion binding and controlled aggregation of human interleukin-1 receptor antagonist. , 2005, Biochemistry.
[58] G. Gregoriadis,et al. Polysialic acids: potential in improving the stability and pharmacokinetics of proteins and other therapeutics , 2000, Cellular and Molecular Life Sciences CMLS.
[59] M. Treuheit,et al. Mono-N-terminal poly(ethylene glycol)-protein conjugates. , 2002, Advanced drug delivery reviews.
[60] A. Malavalli,et al. Toxicity and hemodynamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeys. , 2007, Translational research : the journal of laboratory and clinical medicine.
[61] D. Brems,et al. Inverse Relationship of Protein Concentration and Aggregation , 2002, Pharmaceutical Research.
[62] D. Kalonia,et al. Removal of peroxides in polyethylene glycols by vacuum drying: Implications in the stability of biotech and pharmaceutical formulations , 2006, AAPS PharmSciTech.
[63] H. Mach,et al. High-dose monoclonal antibodies via the subcutaneous route: challenges and technical solutions, an industry perspective. , 2012, Therapeutic delivery.
[64] J. Kressler,et al. Enzymatically catalyzed HES conjugation using microbial transglutaminase: Proof of feasibility. , 2009, Journal of pharmaceutical sciences.
[65] Willem P C Stemmer,et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner , 2009, Nature Biotechnology.
[66] P. Taupin,et al. PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals , 2009 .
[67] A. Minton,et al. Influence of macromolecular crowding upon the stability and state of association of proteins: predictions and observations. , 2005, Journal of pharmaceutical sciences.
[68] Robert W. Payne,et al. Product development issues for PEGylated proteins , 2011, Pharmaceutical development and technology.
[69] Wei Wang,et al. Protein aggregation--pathways and influencing factors. , 2010, International journal of pharmaceutics.
[70] Nitin Rathore,et al. Variability in Syringe Components and its Impact on Functionality of Delivery Systems , 2011, PDA Journal of Pharmaceutical Science and Technology.
[71] J. Kressler,et al. Benchtop-MRI for in vivo imaging using a macromolecular contrast agent based on hydroxyethyl starch (HES). , 2011, International journal of pharmaceutics.
[72] W. Friess,et al. FTIR and nDSC as Analytical Tools for High-Concentration Protein Formulations , 2006, Pharmaceutical Research.
[73] T. Neff,et al. Pharmacokinetics of Hydroxyethyl Starch , 2005, Clinical pharmacokinetics.
[74] A. Klibanov,et al. Hydrophobic salts markedly diminish viscosity of concentrated protein solutions , 2011, Biotechnology and bioengineering.
[75] Interleukin-1 Receptor Antagonist Protein : Solution Secondary Structure from NOE ' s and 1 H « and 13 C « Chemical Shifts , 2007 .
[76] G. Maurer,et al. Osmotic Virial Coefficients of Aqueous Poly(ethylene glycol) from Laser-Light Scattering and Isopiestic Measurements , 1995 .
[77] F. Davis,et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. , 1977, The Journal of biological chemistry.
[78] M. Emgenbroich,et al. AGEM400(HES), a Novel Erythropoietin Mimetic Peptide Conjugated to Hydroxyethyl Starch with Excellent In Vitro Efficacy , 2010 .
[79] F. Veronese,et al. Protein PEGylation, basic science and biological applications , 2009 .